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a b s t r a c t
HIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efﬁciently with
the inferred germline precursors of known broadly neutralizing antibodies (bNAbs). This deﬁciency may be
one reason why Env and Env-based immunogens are not efﬁcient at inducing bNAbs. We evaluated the
binding of 15 inferred germline precursors of bNAbs directed to different epitope clusters to three soluble
native-like SOSIP.664 Env trimers. We found that native-like SOSIP.664 trimers bind to some inferred
germline precursors of bNAbs, particularly ones involving the V1/V2 loops at the apex of the trimer. The
data imply that native-like SOSIP.664 trimers will be an appropriate platform for structure-guided design
improvements intended to create immunogens able to target the germline precursors of bNAbs.
& 2015 Elsevier Inc. All rights reserved.
To be effective, a HIV-1 vaccine should elicit bNAbs that target
the trimeric Env spike on the virion surface (van Gils and Sanders,
2014). No Env immunogen has been able to elicit bNAbs in animals
or humans, but 20% of HIV-1-infected patients do eventually
develop these antibodies after 2–3 years, and some exceptional
patients develop bNAbs within a year (van den Kerkhof et al.,
2014). Longitudinal analyses have shown that bNAbs generally
emerge through a co-evolutionary process that is driven by
iterative cycles of HIV-1 escape from more narrowly focused NAbs,
followed by renewed Ab afﬁnity maturation (Doria-Rose et al.,
2014; Liao et al., 2013).
To generate bNAbs by vaccination, it may be necessary to mimic
such afﬁnity maturation pathways (Haynes et al., 2012). Initiating
any particular bNAb lineage requires activating the naïve B cells
through their B cell receptor, i.e. the unmutated germline antibody
(Haynes et al., 2012). For this to happen in a vaccine setting, the
Env-based immunogen should, therefore, be capable of binding
germline antibodies that have the potential to evolve into bNAbs.
A complication is that most HIV-1 isolates appear incapable of
interacting with the germline versions of bNAbs, which may be the
outcome of how HIV-1 immune evasion strategies have evolved
over time. In consequence, most recombinant Env proteins also
cannot engage the inferred germline precursors of known bNAbs
(gl-bNAbs) (Hoot et al., 2013; McGuire et al., 2013a), either because
they adopt non-native conformations or because they are derived
from viruses that also lack the required reactivity. The problem is
not universal, in that some Env proteins based on autologous
founder virus sequences isolated from the patient from which a
particular bNAb was isolated can sometimes bind the germline
precursor of that bNAb (Doria-Rose et al., 2014; Liao et al., 2013;
Lynch et al., 2015). Furthermore, Env immunogens can be speciﬁ-
cally engineered to have such properties (Dosenovic et al., 2015;
Jardine et al., 2013, 2015; McGuire et al., 2013b).
Recently, several soluble, recombinant SOSIP.664 Env trimers
from clades A (isolate BG505), B (isolate B41) and C (isolates
ZM197M and DU422) have been described (Pugach et al., 2015;
Sanders et al., 2013; Julien et al., 2015). Electron microscopy
imaging, glycan proﬁling and antigenicity studies show that these
SOSIP.664 trimers mimic the virion-associated Env trimer
(Pritchard et al., 2015; Pugach et al., 2015; Sanders et al., 2013;
Julien et al., 2015). In addition, the BG505 and B41 SOSIP.664
trimers have induced consistent NAb responses against the auto-
logous tier 2 viruses, which has not been achieved by non-native
Env immunogens (Sanders et al., 2015).
Whether native-like trimers such as the above SOSIP.664
proteins can interact with gl-bNAbs is clearly relevant to strategies
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intended to induce neutralization breadth. There are reasons to
believe that trimers that do so may be desirable. First, only native-
like trimers consistently present several quaternary structure-
dependent bNAb epitopes at the V1V2-apex or the gp120/gp41
interface (Blattner et al., 2014; Huang et al., 2014; Sanders et al.,
2013). Second, native-like trimers force the appropriate restric-
tions on the selection of Abs with the correct, trimer-compatible
angles of approach, and thereby limit the exposure of immuno-
dominant non-neutralizing epitopes that could interfere with the
triggering of the desired bNAb germline (McGuire et al., 2014;
Sanders et al., 2013; Tran et al., 2014). We have, therefore, assessed
whether the BG505, B41 and ZM197M SOSIP.664 trimers can
interact with a set of 15 gl-bNAbs.
Epitope-tagged SOSIP.664-D7324 or SOSIP.664-His trimers,
expressed in 293F cells, were puriﬁed by PGT145 bNAb-afﬁnity
chromatography (Pugach et al., 2015). We used ELISA and, in some
cases, surface plasmon resonance (SPR) methods to assess trimer
binding to 15 gl-bNAbs, targeting ﬁve distinct Env epitope clusters:
the CD4 binding site (CD4bs) (VRC01, 3BNC60, 1NC9, CH103,
CH31); the glycan-dependent V3 cluster (PGT121, PGT128); the
V1V2-apex (PG9, PG16, PGT145, VRC26.09, CH01) (Doria-Rose
et al., 2014; West et al., 2014); the gp120/gp41 interface (PGT151,
35O22) (Blattner et al., 2014; Huang et al., 2014); gp41 (3BC315)
(Lee et al., 2015). We did not test binding to gp120 monomers or
uncleaved gp140 proteins, since the mature versions of PG9, PG16,
PGT145, VRC26.09, PGT151, 35O22 and 3BC315 have been reported
to bind these proteins very inefﬁciently (Blattner et al., 2014;
Doria-Rose et al., 2014; Huang et al., 2014; Ringe et al., 2013;
Yasmeen et al., 2014; Lee et al., 2015).
The sequences of germline versions of PG9, PGT145, PGT151,
35O22, PGT128, 1NC9, 3BC315 were inferred using the IMGT/V
QUEST online tools (Giudicelli et al., 2004) (Table 1). We note that
PG9 and PG16 are clonal relatives and originate from the same
germline precursor (Pancera et al., 2010). However, it is difﬁcult to
infer an accurate germline sequence of the long heavy chain
complementarity-determining regions 3 (HCDR3) of these anti-
bodies. Therefore, we used two different germline precursors of
the PG9/16 lineage: gl-PG16 was based on the previously pub-
lished sequence (Pancera et al., 2010) and gl-PG9 was inferred as
described above. The gl-bNAb sequences were synthesized by
Genscript, cloned into the pVRC8400 expression vector, trans-
fected into 293F cells and then puriﬁed by a protein A/G agarose
column (Thermo Scientiﬁc). The mature and germline versions of
PG9, PG16 and PGT145 were expressed in the presence of
exogenous tyrosylprotein sulfotransferase 1 (TPST1) to ensure
they were tyrosine-sulfated (Julien et al., 2013). The germline
versions of 3BNC60, VRC01, CH31, CH103, PGT121, CH01 and
VRC26 were kindly provided by colleagues (Table 1). The ELISA
for measuring Ab-trimer binding was modiﬁed from a published
method (Sanders et al., 2013), as follows: 3 μg/ml of SOSIP.664-
D7324 proteins were diluted in Tris-buffered saline pH 7.5 (TBS)
containing 10% fetal calf serum (FCS), and captured on D7324 Ab-
coated plates. Mature and gl-bNAbs were serially diluted in casein-
blocking solution (Thermo Scientiﬁc). Half-maximal binding Ab
concentrations (EC50) were derived using Graphpad Prism (version
5.01). All 15 mature bNAbs bound to all three SOSIP.664-D7324
trimers, which is mostly consistent with the antigenicity proﬁles
reported previously (Pugach et al., 2015; Sanders et al., 2013;
Julien et al., 2015) (Table 2). We note that, here, the mature
versions of PGT151 and 35O22 were reactive with the B41
SOSIP.664 trimers in ELISA (Table 2), which was not seen in our
previous study (Pugach et al., 2015). The difference may arise
because we increased the assay sensitivity by using a higher input
concentration of the B41 SOSIP.664-D7324 trimer (i.e., 3 mg/ml vs.
0.3 mg/ml, previously) and we used a different blocking solution
(i.e., casein blocking solution vs. 2% milk, previously).
The BG505 SOSIP.664-D7324 trimer bound to gl-PG9 and its
somatic relative gl-PG16 (EC50: 1.0 and 15 μg/ml, respectively), its
ZM197M counterpart bound to gl-PG9 (EC50: 6.8 μg/ml) but not gl-
PG16, while the B41 trimer bound neither glPG9 nor glPG16 (Fig. 1
and Table 2). Compared to gl-PG16, gl-PG9 contains more tyrosines
that are potentially sulfated, which could increase afﬁnity for the
cationic groove at the trimer apex. This might explain the increased
reactivity of gl-PG9 with BG505 and ZM197M SOSIP.664 trimers.
The BG505 and B41 trimers also bound to gl-CH01 (EC50: 0.64 and
1.0 μg/ml respectively). Gl-VRC26 and gl-PGT145, which bind to a
similar epitope as PG9 and PG16, but have entirely different HCDR3
loops and are derived from different germline genes, did not bind to
any of the SOSIP.664 trimers. We observed a remarkably high
afﬁnity interaction between gl-3BC315 and the BG505 and
ZM197M trimers (EC50: 0.27; 0.54 μg/ml respectively) (Fig. 1 and
Table 2). We note, however, that the HCDR3 of the germline- and
mature versions of 3BC315 were identical, since it was not possible
to reliably infer the germline HCDR3 sequence from the mature
Table 1
Putative gene usage and CDR3 sequences of the gl-bNAbs used in this study.
Antibody VH-gene HCDR3a JH-gene VL-gene LCDR3a JL-gene Source Reference
PG9 V3-33n05 AREAGGPDYRNGYNYYDFWSGYYTYYYMDVb J6n03 LV2-14n01 SSYTSSSTLV LJ3n02 IMGT N.A.
PG16 V3-33n05 AREAGGPIWHDDVKYYDFNDGYYNYHYMDV J6n03 LV2-14n01 SSYTSSSTLV LJ3n02 P. Kwong Pancera et al., 2010
PGT145 V1-8n01 GSKHRLRDYFLYNEYGPNYEEWGDYLATLDVc J6n02 KV2-28n01 MQALQTPWT KJ1n01 IMGT N.A.
VRC26.09 V3-30n18 CAKDLGESENEEWAYDYYDFSIGYPGQ
DPRGVVGAFDIW
J3n02 LV1-50n02 GTWDSSLSAGGVF LJ1-02 J. Mascola Doria-Rose et al., 2014
CH01 V3-20n01 GTDYTIDDQGIRYQGSGTFWYFDL J2n01 KV3-20n01 CQQYGSSPYTF KJ1n01 B. Haynes&H. Liao Bonsignori et al., 2011
VRC01 V1-2n02 ARGKNSDYNWDFQH J2n01 KV3-11n01 CQQYEFF KJ2n01 W. Schief Jardine et al., 2013
3BNC60 V1-2n02 ARQRSDFWDFDL J2n01 KV1-33n01 CQQYEFI KJ3n01 M. Nussenzweig Scheid et al., 2011
CH31 V1-2n02 ARAQKRGRSEWAYAH J4n02 KV1-33n01 CQQYETF KJ2n01 B. Haynes&H. Liao Wu et al., 2011
CH103 V4-59n01 SLPRGQLVNAYFDY J4n02 LV3-1n01 CQAWDSFSTFV LJ1n01 B. Haynes&H. Liao Liao et al., 2013
1NC9 V1-46n01 QDSDFHDGHGHTLRGMFDYc J4n02 LV1-47n01 CAAWDDSLSGPVF LJ2n01 IMGT N.A.
PGT121 V4-59n01 TLHGRRIYGIVAFNEWFTYFYMDV J6n03 LV3-21n02 QVWDSRVITKWV LJ3n02 M. Nussensweig N.A.
PGT128 V4-39n07 FGGEVLRFLEWPKPAWFDPb J5n02 LV2-8n01 SSYAGNWDVV LJ2n01 IMGT N.A.
PGT151 V3-30n04 ARMFQESGPPRLDRWSGRNYYYYYGMDVc J6n02 KV2D-29n02 MQSKDFPLT KJ4n01 IMGT N.A.
35O22 V1-18n02 GLLRDGSSTWLPYLc J4n02 LV2-14n02 SSYTSSSGCV LJ1n01 IMGT N.A.
3BC315 V1-2n02 PMRPVSHGIDYSGLFVFQFc J3n01 LV2-23n02 CSYANYDKLI LJ3n01 IMGT N.A.
a The CDR3 was deﬁned based on www.bnaber.org when available or by using www.imgt.org.
b The N region of the junction between the genes V and D was taken from the mature sequence, since reversion was not possible. The rest of the sequence was inferred
by combining D and J genes.
c The CDR3 sequence was taken from the mature version whenever the D gene generated by IMGT did not provide an acceptable match to the mature nucleotide
sequence.
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version. As the HCDR3 of 3BC315 is known to make important
hydrophobic contacts with the gp41/gp120 interface (Lee et al.,
2015), this interaction may contribute to the high afﬁnity the gl-
3BC315 antibody has for the BG505 and ZM197M trimers. However,
as gl-3BC315 did not bind to the B41 trimers, there are complexities
to the Ab-trimer binding events that remain to be understood,
such as the involvement of topologically proximal glycans
in either the formation or the occlusion of the epitope (Lee et al.,
2015).
None of the three trimers bound the gl-bNAbs targeting the
glycan-dependent V3 epitopes (PGT121 and PGT128). They also
did not interact detectably with the VRC01, 3BNC60, 1NC9 or CH31
gl-bNAbs against the CD4bs, perhaps because of the shielding
effects of various trimer glycans. An example is the clash between
the N276 glycan and the gl-VRC01 light chain (McGuire et al.,
2013b). While gl-CH103 was prone to generating a high level of
non-speciﬁc background signals in ELISA (Fig. 1, “gl-CH103 mock”),
we did detect some speciﬁc binding of this antibody to the
ZM197M trimers (EC50: 18.1 μg/ml) although not to their BG505
and B41 counterparts (Fig. 1 and Table 2).
To corroborate the binding of gl-PG16 to the BG505 SOSIP.664-
D7324 trimers, we performed SPR analyses using the His-tagged
version of the same trimers. The data were ﬁtted with a bivalent
model, and binding parameters for the monovalent component in
the bivalent model are given (Yasmeen et al., 2014). We conﬁrmed
that gl-PG16 bound to BG505 SOSIP.664-His trimers, although with
a lower afﬁnity (dissociation constant, Kd¼320 nM) than mature
PG16 (Kd¼24 nM) (Fig. 2A). The reduced afﬁnity arises because kon
(on-rate constant) and koff (off-rate constant) were 5-fold lower
and 3-fold higher, respectively, for gl-PG16 (Fig. 2B). As the
binding stoichiometry was also lower for gl-PG16 (Sm¼0.4) than
for mature PG16 (Sm¼1.3) only a subset of the trimers can bind gl-
PG16, perhaps because of variation in the presence or composition
of particular glycan sites (Fig. 2B). The difference in binding to
BG505 SOSIP.664 between gl-PG16 and mature PG16 were more
substantial in ELISA (EC50 values¼13.1 μg/ml and 0.031 μg/ml,
respectively) than in SPR (Kd¼320 nM and 24 nM, respectively).
This can probably be explained by the high off-rate, which results in
loss of binding signal in ELISA during washing steps. We note that
the BG505 trimers are based on a transmitter/founder virus
sequence that is similar in the relevant regions to viruses isolated
from the donor of the PG9 and PG16 bNAbs (Hoffenberg et al., 2013;
Sanders et al., 2013). This sequence homology may help explain
why gl-PG9 and gl-PG16 bind to the BG505 trimers. In contrast, but
consistent with the ELISA data, gl-VRC01 did not bind to BG505
SOSIP.664-His trimers in the SPR assay (Fig. 2A).
Table 2
Summary of EC50 values (in ng/ml) derived from D7324-capture ELISA with different SOSIP.664 trimers.

























Germline Mature Mature Germline Mature Mature Germline Mature Mature
PG9 935 40 45 * >25000 242 560 * 6769 103 393 *
PG16 13100 31 8 * >25000 65 80 * >25000 77 49 *
PGT145 >25000 12 83 * >25000 67 60 >25000 27 393 *
VRC26.09 >25000 31 <10 >25000 1204 >25000 >25000 50 4 *
CH01 640 58 301 * 1003 44 N.D. >25000 2044 N.D.
VRC01 >25000 9 70 * >25000 34 1380 * >25000 7 329 *
3BNC60 >25000 21 34 * >25000 55 11 >25000 58 77
1NC9 >25000 209 251 * >25000 355 1961 >25000 128 1006*
CH103 >25000 179 2572 * >25000 2412 >25000 18090 143 18222
CH31 >25000 13 14 * >25000 32 26 >25000 48 358
PGT121 >25000 61 15 * >25000 147 920 * >25000 35 35 *
PGT128 >25000 12 11 * >25000 46 414 >25000 6 33 * <250
PGT151 >25000 28 1 >25000 126 300 * >25000 30 2 * 250-2500
35O22 >25000 379 8 >25000 1052 >25000 >25000 463 2816 * 2500-25000
























Fig. 1. Representative binding curves of a panel of mature and gl-bNAbs tested in the same ELISA. We note that all mature (bottom) and gl-bNAbs (top) generated
comparable and low background signals in this ELISA format (“mock”: the wells contained only 10% FCS in TBS), except gl-CH103, for which the background was considerably
higher (“gl-CH103 mock”).
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Gl-bNAb sequences are based on in silico predictions. Whether
these inferred gl-bNAbs truly represent the in vivo naïve B cell
receptors remains to be determined. Nevertheless, this exploratory
study indicates that various SOSIP.664 trimers can bind to several
gl-bNAbs, mainly ones that are directed to the V1/V2 loops. Hence
these trimers are good starting points for engineering immunogens
that more efﬁciently activate naïve B cell receptors and thereby
initiate pathways that lead to the eventual emergence of bNAbs.
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